Silverberg JI, Simpson EL, Wollenberg A, et al. - In this long-term double-blind extension study of 2 randomized clinical trials, researchers sought to assess the long-term (68-week) effectiveness of baricitinib, an oral selective Janus kinase inhibitor, in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders in BREEZE-AD1 and BREEZE-AD2. Patients who were initially randomized to 4 or 2 mg baricitinib and were classified as responders or partial responders at the start of BREEZE-AD3 stayed on their original doses. Of the 1,239 patients enrolled in BREEZE-AD1/BREEZE-AD2, 1,081 (87.2%) registered in BREEZE-AD3. The results of this study show that baricitinib (4 and 2 mg) has long-term efficacy (up to 68 weeks) in adults with moderate to severe atopic dermatitis. Overall, these findings suggest that baricitinib may be a viable long-term treatment option for patients with moderate to severe atopic dermatitis.